Vancosol Injection (500mg & 1g) - Glycopeptide Antibacterial Therapy for Severe Resistant Infections

Product Overview

Vancosol Injection is a potent, broad-spectrum parenteral glycopeptide antibacterial formulation containing Vancomycin Hydrochloride. Formulated for slow Intravenous (IV) infusion, Vancosol serves as a critical first-line antibiotic for severe, complicated, and multi-drug-resistant Gram-positive bacterial infections. It is specifically indicated for the management of infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA) and co-agulase-negative staphylococci, including severe sepsis, infective endocarditis, lower respiratory tract infections (nosocomial pneumonia), bone and joint infections (osteomyelitis), complicated skin and soft tissue structure infections, and catheter-related bloodstream infections.

Key Benefits

\n
• \n

  Gold Standard Against MRSA: Unmatched bactericidal efficacy against Methicillin-Resistant Staphylococcus aureus and resistant enterococcal strains.

  \n
\n
• \n

  Targeted Inpatient Critical Care: Primary therapy for severe hospital-acquired pneumonia, septicemia, and complicated prosthetic joint infections.

  \n
\n
• \n

  Essential Alternative for Beta-Lactam Hypersensitivity: Provides vital anti-staphylococcal and anti-streptococcal coverage in patients with severe penicillin/cephalosporin allergies.

  \n
\n
• \n

  High Tissue Concentration: Achieves effective bactericidal concentrations in heart valves, bone, pulmonary tissue, and peritoneal fluid.

  \n
\n
• \n

  Flexible Dosing Strengths (500mg & 1g): Facilitates precise body-weight and therapeutic drug monitoring (TDM) dosage adjustments.

  \n
\n

How It Works

Vancosol Injection (Vancomycin HCl) exerts its bactericidal effect by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors. This binding sterically inhibits the transglycosylation and transpeptidation steps required for peptidoglycan polymerization and cross-linking, causing structural failure of the bacterial cell wall. Additionally, Vancomycin alters bacterial cell membrane permeability and selectively inhibits RNA synthesis, providing multi-target bactericidal activity against dividing Gram-positive bacteria.

WooCommerce Attribute / Variation Details

Variation 1: VANCOSOL INJ 500MG

\n
• \n

  SKU: VAN-INJ-500

  \n
\n
• \n

  Short Description: Ideal for pediatric regimens, step-down maintenance dosing, and precise dose titration in patients with renal impairment.

  \n
\n
• \n

  Key Active Ingredient: Vancomycin Hydrochloride — equivalent to 500mg Vancomycin per vial.

  \n
\n
• \n

  Target Indications: Pediatric MRSA infections, weight-adjusted dosing, and dose-modified regimens for compromised renal clearance.

  \n
\n
• \n

  Standard Dosing: Administered via slow IV infusion (over at least 60 minutes) every 6 to 12 hours based on therapeutic drug monitoring (TDM) serum trough levels.

  \n
\n

Variation 2: VANCOSOL INJ 1G

\n
• \n

  SKU: VAN-INJ-1G

  \n
\n
• \n

  Short Description: Standard adult clinical strength for acute inpatient management of severe MRSA bacteremia, nosocomial pneumonia, and endocarditis.

  \n
\n
• \n

  Key Active Ingredient: Vancomycin Hydrochloride — equivalent to 1g Vancomycin per vial.

  \n
\n
• \n

  Target Indications: Severe MRSA sepsis, infective endocarditis, complicated osteomyelitis, hospital-acquired pneumonia, and surgical site infections.

  \n
\n
• \n

  Standard Dosing: Administered 1g via slow IV infusion (over at least 100 to 120 minutes) every 12 hours for adults with normal renal function.

  \n
\n

General Product Details (Shared across variations)

Key Active Ingredients

\n
• \n

  Vancomycin Hydrochloride (500mg / 1g per vial): Parenteral glycopeptide antibiotic that inhibits bacterial cell wall peptidoglycan synthesis in Gram-positive pathogens.

  \n
\n

Directions for Use

\n
1. \n

   Reconstitution: Reconstitute the dry powder vial by adding 10ml (for 500mg) or 20ml (for 1g) of Sterile Water for Injection to yield a 50mg/ml solution.

   \n
\n
2. \n

   Dilution: Reconstituted solution must be diluted further in at least 100ml (for 500mg) or 200ml (for 1g) of 0.9% Sodium Chloride Injection or 5% Dextrose Injection to achieve a concentration of not more than 5mg/ml.

   \n
\n
3. \n

   Infusion Rate & Route: Strictly for Intravenous (IV) Infusion. Do NOT give via intramuscular or rapid bolus IV injection.

   \n \n
   \n
   • \n

     Infuse at a rate of no more than 10mg/min (or over at least 60 minutes for 500mg, and at least 100–120 minutes for 1g).

     \n
   \n
   \n
\n
4. \n

   Professional Healthcare Use: Must be administered exclusively under direct medical supervision in a hospital setting with therapeutic drug monitoring (TDM) capabilities.

   \n
\n

Precautions

\n
• \n

  Prescription-Only Parenteral: For inpatient hospital and specialized clinical administration only; strictly avoid self-administration.

  \n
\n
• \n

  "Red Man Syndrome" Warning: Rapid IV bolus administration can trigger histamine release leading to severe hypotension, flushing, and a maculopapular rash on the face, neck, and upper torso. Always maintain slow infusion rates.

  \n
\n
• \n

  Ototoxicity & Nephrotoxicity: May cause hearing loss or renal failure, particularly when combined with other nephrotoxic/ototoxic agents (e.g., aminoglycosides). Regular monitoring of serum renal function and serum Vancomycin trough levels is required.

  \n
\n
• \n

  Extravasation Risk: Infuse into a large vein or central line to avoid severe local tissue necrosis or thrombophlebitis.

  \n
\n
• \n

  Consult an attending physician before use during pregnancy or lactation.

  \n
\n
• \n

  Keep out of reach of children.

  \n
\n

Storage Instructions

Store the un-reconstituted dry powder vial below 30°C, protected from light and heat. Once reconstituted and diluted in compatible IV fluids, the solution is stable for 14 days under refrigeration (2∘C to 8∘C) or 24 hours at room temperature (25∘C). Do not freeze.

Manufacturer Information

Formulated and manufactured in strict compliance with international pharmaceutical quality standards, dedicated to engineering essential anti-infective parenteral formulations to fight drug-resistant pathogens and safeguard inpatient recovery.